REGN vs SPRB · P/E 14, rev $14.34B vs rev $4.9M
Regeneron Pharmaceuticals Inc (REGN) versus Spruce Biosciences Inc (SPRB) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Spruce Biosciences Inc (SPRB) is a biotechnology company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SPRB revenue for 2024-12-31 was $4.9M. Net income was -$53.0M. Revenue was down 51.3% from 2023-12-31 to 2024-12-31. SPRB currently screens at market cap $3.0M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SPRB currently screens at market cap $3.0M.
Not investment advice. Open the REGN and SPRB stock pages for the full models.
Not investment advice.